Overview
- Nuclera added $12 million to its Series C, led by Elevage Medical Technologies and Jonathan Milner with continued support from the British Business Bank and GK Goh.
- The new financing focuses on integrating expression, purification, and binding validation of full-format antibodies on a single high-throughput system.
- The eProtein Discovery platform combines cell-free expression, digital microfluidics, and screening data to shorten protein workflow timelines and produce reproducible outputs.
- Recent progress includes a membrane protein workflow, a collaboration with Cytiva, expanded access across APAC and the Middle East, and a first CRO installation at Domainex.
- Nuclera reported its first commercial sales in Asia with installations at National Taiwan University and National Cheng Kung University, signaling growing global adoption.